Quarterly report pursuant to Section 13 or 15(d)

ACCRUED EXPENSES

v3.21.2
ACCRUED EXPENSES
6 Months Ended
Jun. 30, 2021
Payables and Accruals [Abstract]  
ACCRUED EXPENSES

10. ACCRUED EXPENSES

 

Accrued expenses consisted of the following:

 

    June 30, 2021     December 31, 2020  
             
Accrued clinical operations and trials costs   $ 10,376,840     $ 14,132,842  
Accrued product development costs     533,402       2,189,047  
Accrued compensation     2,669,184       4,222,594  
Accrued other     1,508,255       1,460,949  
Total   $ 15,087,681     $ 22,005,432